Ketogenic and Low FODMAP Diet in Therapeutic Management of a Young Autistic Patient with Epilepsy and Dysmetabolism Poorly Responsive to Therapies: Clinical Response and Effects of Intestinal Microbiota.
Study Goal
The researchers aimed to determine whether a low-FODMAP diet could improve neurological, metabolic, and intestinal symptoms in a patient with ASD and associated gut microbiota dysbiosis.
Results Summary
The low-FODMAP diet significantly improved neurological, intestinal, and metabolic symptoms, was well-tolerated, and modulated gut microbiota composition by reducing Actinobacteria, Firmicutes, Lactobacilli, and Bifidobacteria while increasing alpha biodiversity and decreasing the Firmicutes/Bacteroidetes ratio.
Population
A 17-year-old girl with ASD, reduced growth, neurological development delay, and intestinal disorders.
Effective Dosage
Not specified
Duration
Not specified
Interactions
None mentioned
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
ketogenic diet | decrease | Firmicutes, Bacteroidetes, and Proteobacteria | 17-year-old girl affected by ASD | - | provided a reduction | #1 |
ketogenic diet | increase | intestinal symptoms | 17-year-old girl affected by ASD | - | improved | #2 |
low FODMAPs diet | increase | all neurological, intestinal, and metabolic symptoms | 17-year-old girl affected by ASD | - | produced a significant improvement | #3 |
low FODMAPs diet | decrease | Actinobacteria, Firmicutes, Lactobacilli, and Bifidobacteria | 17-year-old girl affected by ASD | - | showed reductions | #4 |
low FODMAPs diet | increase | alpha biodiversity | 17-year-old girl affected by ASD | - | consistently increased | #5 |
low FODMAPs diet | decrease | Firmicutes/Bacteroidetes ratio | 17-year-old girl affected by ASD | - | decreased | #6 |
low FODMAPs diet | decrease | extent of fermentative dysbiosis | 17-year-old girl affected by ASD | - | reducing | #7 |
Autism spectrum disorder (ASD) is often associated with several intestinal and/or metabolic disorders as well as neurological manifestations such as epilepsy (ASD-E). Those presenting these neuropathological conditions share common aspects in terms of gut microbiota composition. The use of microbiota intervention strategies may be an approach to consider in the management of these cases. We describe the case of a 17-year-old girl affected by ASD, reduced growth, neurological development delay, mutations in the PGM1 and EEF1A2 genes (in the absence of clinically manifested disease) and, intestinal disorders such as abdominal pain and diarrhea associated with weight loss. As she demonstrated poor responsiveness to the therapies provided, we attempted two specific dietary patterns: a ketogenic diet, followed by a low fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAP) diet, with the aim of improving her neurological, metabolic, and intestinal symptoms through modulation of the gut microbiota's composition. The ketogenic diet (KD) provided a reduction in Firmicutes, Bacteroidetes, and Proteobacteria. Although her intestinal symptoms improved, KD was poorly tolerated. On the other hand, the passage to a low FODMAPs diet produced a significant improvement in all neurological, intestinal, and metabolic symptoms and was well-tolerated. The following gut microbiota analysis showed reductions in Actinobacteria, Firmicutes, Lactobacilli, and Bifidobacteria. The alpha biodiversity was consistently increased and the Firmicutes/Bacteroidetes ratio decreased, reducing the extent of fermentative dysbiosis. Gut microbiota could be a therapeutic target to improve ASD-related symptoms. Further studies are needed to better understand the correlation between gut microbiota composition and ASD, and its possible involvement in the physiopathology of ASD.